UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934
October 25, 2004
Date of Report (date of Earliest Event Reported)
ISOLAGEN, INC.
(Exact Name of Registrant as Specified in its Charter)
DELAWARE (State or Other Jurisdiction of Incorporation or Organization) |
001-31564 (Commission File No.) |
87-0458888 (I.R.S. Employer Identification No.) |
2500 Wilcrest, 5th Floor, Houston, Texas 77042
(Address of principal executive offices and zip code)
(713) 780-4754
(Registrant's telephone number, including area code)
Not applicable
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Item 7.01 Regulation FD Disclosure
Isolagen announces proposed convertible subordinated notes offering. See Exhibit 99.1 for details.
Item 9.01 Financial Statements and Exhibits
[THE SIGNATURE PAGE FOLLOWS.]
2
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ISOLAGEN, INC. | |||
Date: October 25, 2004 |
By: |
/s/ JEFFREY TOMZ Chief Financial Officer |
3